Engineered vesicles comprising antigenic peptides and the uses thereof as modulators of immune responses
US10258683B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 27, 2016 |
| Grant date | Apr 16, 2019 |
| Priority date | — |
| Expiry date | Aug 11, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/36171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are single nucleic acid constructs comprising a vector, wherein the vector comprises: a first nucleic acid sequence, wherein the first nucleic acid sequence comprises one or more antigenic sequences of interest, one or more spacer sequences and one or more hydrophobic anchor sequences, operably linked to a first transcriptional control element; a second nucleic acid sequence, wherein the second nucleic acid sequence comprises one or more pathogen-associated molecular pattern (PAMP) sequences operably linked to a second transcriptional control element; a third nucleic acid sequence, wherein the third nucleic acid sequence comprises one or more cell surface receptor binding sequences operably linked to a third transcriptional control element; and a selectable marker. Also described herein, are methods of making the single nucleic acid constructs and methods of administering the single nucleic acid constructs for the treatment or prevention of infections and cancer. Also described herein are cell lines and engineered vesicles made using the single nucleic acid constructs described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.